What is the best treatment for a persistent post‑COVID‑19 cough in an otherwise healthy adult?

Treatment of Post-COVID Cough

For persistent post-COVID cough, inhaled ipratropium bromide (2–3 puffs four times daily) is the first-line pharmacologic treatment with the strongest evidence, followed by inhaled corticosteroids (ICS/LABA) if quality of life remains impaired after 1–2 weeks.

Definition and Timeline

• Post-COVID cough is diagnosed when cough persists for 3–8 weeks following acute COVID-19 infection, based on clinical presentation and timeline 1.
• If cough extends beyond 8 weeks, it must be reclassified as chronic cough and systematically evaluated for alternative causes including upper airway cough syndrome, asthma, and gastroesophageal reflux disease 1, 2.
• The pathophysiology involves heightened cough reflex sensitivity driven by viral neurotropism, neuroinflammation, and ongoing airway inflammation 3, 4.

Evidence-Based Treatment Algorithm

First-Line: Supportive Care (Weeks 1–3)

• Honey and lemon provide symptomatic relief through central modulation of the cough reflex and are recommended as initial therapy for patients over 1 year of age 5, 2.
• Guaifenesin (200–400 mg every 4 hours, up to 6 times daily) helps loosen phlegm and is a safe over-the-counter option 1.
• Maintain adequate hydration (no more than 2 liters daily) and avoid lying flat, which makes coughing ineffective 5.
• Dextromethorphan 60 mg provides maximum cough reflex suppression and is preferred over codeine due to fewer adverse effects 2.

Second-Line: Inhaled Ipratropium (Weeks 2–4)

• Inhaled ipratropium bromide 2–3 puffs (17–34 mcg per puff) four times daily has the strongest controlled-trial evidence for attenuating post-infectious cough, with response expected within 1–2 weeks 1, 2.
• This should be initiated when quality of life is significantly affected or symptoms persist beyond initial supportive care 1.

Third-Line: Inhaled Corticosteroids (Weeks 4–8)

• ICS/LABA combination therapy (e.g., fluticasone 220 mcg or budesonide 360 mcg twice daily) is the most effective treatment based on real-world post-COVID cough data, superior to other agents 6.
• Add inhaled corticosteroids when cough persists despite ipratropium and continues to impair quality of life 1, 2.
• The mechanism involves suppression of airway inflammation and bronchial hyperresponsiveness; allow up to 8 weeks for full therapeutic response 1.
• Elevated fractional exhaled nitric oxide (FeNO ≥25 ppb) is seen in 44.7% of post-COVID cough patients and may predict corticosteroid responsiveness 7.

Fourth-Line: Oral Corticosteroids (Severe Cases Only)

• Oral prednisone 30–40 mg daily for 5–10 days is reserved exclusively for severe paroxysmal cough that substantially impairs quality of life 1, 2.
• This should only be prescribed after ruling out upper airway cough syndrome, asthma, and GERD as contributing factors 1, 2.

Refractory Cough: Neuromodulators

• When all standard therapies fail, consider gabapentin as the first-choice neuromodulator for chronic refractory cough 8.
• Alternative neuromodulators include opioids (codeine, morphine) or macrolides, though these carry greater adverse-effect profiles 2, 8.
• Speech pathology treatment combined with neuromodulators may provide enhanced, longer-duration response 8.

What NOT to Do

• Antibiotics are explicitly contraindicated for post-COVID cough unless there is confirmed bacterial sinusitis or pertussis infection; they provide no benefit, contribute to antimicrobial resistance, and cause adverse effects 1, 5, 2.
• Do not prescribe oral prednisone for mild post-COVID cough; reserve it for severe cases that have failed other therapies 1.
• Do not fail to recognize when cough has persisted beyond 8 weeks, which mandates reclassification and systematic evaluation for chronic cough causes 1, 2.

Special Diagnostic Considerations

• Chest radiograph and spirometry are mandatory if cough persists beyond 8 weeks, or if any red flags develop (hemoptysis, fever, weight loss, night sweats) 1, 2.
• FeNO measurement may be useful for guiding inhaled corticosteroid therapy, as elevated levels (≥25 ppb) are common in post-COVID cough 7.
• Consider bronchoprovocation testing if spirometry is normal but asthma is suspected clinically 9.
• High-resolution CT chest and bronchoscopy should be considered if all empiric therapies fail and imaging is normal 1.

Clinical Characteristics and Prognosis

• Post-COVID cough affects 70% females, with median duration of 8 weeks (interquartile range 4–12 weeks) 6.
• 60% present with dry cough, while 40% have productive cough; over half report abnormal laryngeal sensations 6.
• With guideline-based treatment, 83.3% of patients show significant improvement (Leicester Cough Questionnaire change ≥+1.3) within median 35 days 7.
• Post-COVID cough is clinically similar to non-COVID chronic cough, and current cough guideline approaches are effective in most patients 7.

Multifactorial Causes Requiring Concurrent Treatment

• Chronic cough is frequently multifactorial; partial improvement with one therapy indicates continuing that treatment while adding the next intervention rather than switching 1.
• For upper airway cough syndrome: first-generation antihistamine-decongestant combination plus intranasal corticosteroid, with response in days to 1–2 weeks 1.
• For asthma: inhaled corticosteroids and beta-agonists, with response potentially requiring up to 8 weeks 1.
• For GERD: high-dose PPI therapy (omeprazole 40 mg twice daily) with dietary modifications, with response requiring 2 weeks to several months 1.